Silverarc Capital Management, LLC Portfolio Holdings

Silverarc Capital Management, LLC

  • $414 Million
  • Q2 2025

Silverarc Capital Management, LLC has filed its 13F form on August 14, 2025 for Q2 2025 where it was disclosed a total value porftolio of $414 Million distributed in 65 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Merus N.V. with a value of $39M, Akero Therapeutics, Inc. with a value of $38.1M, Verona Pharma PLC with a value of $33.9M, Uro Gen Pharma Ltd. with a value of $27.7M, and Rhythm Pharmaceuticals, Inc. with a value of $25.3M.

Examining the 13F form we can see an increase of $3.04M in the current position value, from $411M to 414M.

Below you can find more details about Silverarc Capital Management, LLC portfolio as well as his latest detailed transactions.

Portfolio value $414 Million
Healthcare: $414 Million

Stock Holdings Table

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History
$2.93B
$39 Million 9.44% of portfolio
741,972
Q2 2025 Reduced 8.51%
$2.23B
$38.1 Million 9.21% of portfolio
713,811
Q2 2025 Reduced 0.86%
$6.41B
$33.9 Million 8.19% of portfolio
358,297
Q2 2025 Reduced 34.36%
$437M
$27.7 Million 6.7% of portfolio
2,022,482
Q2 2025 Added 46.43%
$5.51B
$25.3 Million 6.12% of portfolio
400,772
Q2 2025 Added 18.71%
$16.5B
$25.1 Million 6.06% of portfolio
249,060
Q2 2025 Reduced 22.5%
$301M
$20.7 Million 5.01% of portfolio
1,832,171
Q2 2025 Added 7.84%
$12.3B
$20.5 Million 4.95% of portfolio
162,969
Q2 2025 Added 124.53%
$420M
$20 Million 4.84% of portfolio
2,037,087
Q2 2025 Added 34.86%
$377M
$18.3 Million 4.42% of portfolio
1,800,829
Q2 2025 Reduced 12.59%
$3.29B
$18 Million 4.35% of portfolio
235,583
Q2 2025 Reduced 46.34%
$10.9B
$14.9 Million 3.61% of portfolio
86,552
Q2 2025 Added 14.26%
$2.06B
$12.1 Million 2.93% of portfolio
448,495
Q2 2025 Reduced 29.24%
$1.66B
$12.1 Million 2.92% of portfolio
341,010
Q2 2025 New
$2.41B
$11.6 Million 2.82% of portfolio
410,000
Q2 2025 Reduced 0.32%
$1.78B
$9.36 Million 2.26% of portfolio
287,796
Q2 2025 New
$181M
$6.33 Million 1.53% of portfolio
5,146,782
Q2 2025 Reduced 18.57%
$127M
$5.4 Million 1.31% of portfolio
3,033,879
Q2 2025 Added 4.78%
$30.7M
$5.39 Million 1.3% of portfolio
2,779,795
Q2 2025 Added 0.31%
$38M
$5.21 Million 1.26% of portfolio
917,898
Q2 2025 New
$1.11B
$4.04 Million 0.98% of portfolio
198,441
Q2 2025 Reduced 3.65%
$13.5M
$4 Million 0.97% of portfolio
2,761,684
Q2 2025 Added 3.43%
$2.04B
$3.87 Million 0.94% of portfolio
82,023
Q2 2025 New
$734M
$3.78 Million 0.91% of portfolio
402,964
Q2 2025 Reduced 69.22%
$228M
$3.51 Million 0.85% of portfolio
2,488,291
Q2 2025 Added 1.29%
$321M
$3.25 Million 0.79% of portfolio
1,249,781
Q2 2025 Added 42.85%
$191M
$3.26 Million 0.79% of portfolio
2,569,591
Q2 2025 Reduced 65.12%
$428M
$2.95 Million 0.71% of portfolio
539,587
Q2 2025 Added 1.81%
$668M
$2.82 Million 0.68% of portfolio
202,565
Q2 2025 Reduced 0.41%
$443M
$1.5 Million 0.36% of portfolio
401,540
Q2 2025 Reduced 9.11%
$93.5M
$1.4 Million 0.34% of portfolio
103,026
Q2 2025 Reduced 46.19%
$590M
$938,000 0.23% of portfolio
3,128,421
Q2 2025 Added 1.29%
$7.86M
$525,000 0.13% of portfolio
710,363
Q2 2025 Reduced 25.92%
$16.4M
$299,000 0.07% of portfolio
1,070,367
Q2 2025 Reduced 73.88%
$1.61B
$65,000 0.02% of portfolio
5,000
Q2 2025 Reduced 97.85%
Structure Therapeutics Inc
-
$0 0.0% of portfolio
-
Q2 2025 Reduced 6.61%
Soleno Therapeutics Inc
-
$0 0.0% of portfolio
-
Q2 2025 Added 22.94%
Tourmaline Bio Inc
-
$0 0.0% of portfolio
-
Q2 2025 New
Benitec Biopharma Inc
-
$0 0.0% of portfolio
-
Q2 2025 Added 1.29%
Sagimet Biosciences Inc
-
$0 0.0% of portfolio
-
Q2 2025 New
Aardvark Therapeutics Inc
-
$0 0.0% of portfolio
-
Q2 2025 Added 140.01%
Sionna Therapeutics Inc
-
$0 0.0% of portfolio
-
Q2 2025 Added 62.97%
Radiopharm Theranostics LTD
-
$0 0.0% of portfolio
-
Q4 2024 New
Fractyl Health Inc
-
$0 0.0% of portfolio
-
Q2 2025 Reduced 14.68%
Enliven Therapeutics Inc
-
$0 0.0% of portfolio
-
Q2 2025 New
Helix Acquisition Corp Ii
-
$0 0.0% of portfolio
-
Q1 2025 Added 19.48%
Dianthus Therapeutics Inc
-
$0 0.0% of portfolio
-
Q2 2025 Reduced 49.66%
Kiniksa Pharmaceuticals Intl
-
$0 0.0% of portfolio
-
Q2 2025 Reduced 13.89%
Metsera Inc
-
$0 0.0% of portfolio
-
Q2 2025 Added 84.09%

Summary

  • Portfolio
  • No. of Stocks 65
  • Current Value $414 Million
  • Prior Value $411 Million
  • Filing
  • Period Q2 2025
  • Filing Date August 14, 2025
  • Form Type 13F-HR
  • Activity in Q2 2025
  • New Purchases 12 stocks
  • Additional Purchases 18 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 24 stocks
Track This Portfolio

Track Silverarc Capital Management, LLC Portfolio

Follow Silverarc Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Silverarc Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Silverarc Capital Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email